Symjepi (epinephrine) 0.3mg and 0.15mg Injections are now available in retail pharmacies, according to Sandoz.
The overall prevalence of Kounis syndrome in the United States is 1.1% among patients hospitalized for allergic/hypersensitivity/anaphylactic reactions, with a 7.0% rate of all-cause inpatient mortality.
Immunoglobulin E reactivity varies significantly in children with asthma and rhinitis in allergic reactions to cockroaches.
The fluticasone exhalation delivery system is a novel topical steroid delivery system that is an important adjunct therapy for sinonasal inflammatory disease.
The Food and Drug Administration (FDA) has approved Dupixent (dupilumab; Sanofi and Regeneron) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.
There is no significant increased benefit in using a higher-dose nasal steroid spray compared with the standard dose after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis.
OCuSOFT Inc. announced the availability of OCuSOFT Lid Scrub Allergy Eyelid Cleanser in pre-moistened pads for use in patients with allergic conditions.
Genentech announced positive topline data from two phase 3 trials, POLYP 1 and POLYP 2, evaluating Xolair (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids.